Work

1329P Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naïve EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results

Year: 2024

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1384

Authors: P. Ma, W. Gao, H. Shen, L. Xu, R. Wang, X. Chen, J. He, Y. Liu, J. Sun, Y. Shu

Institutions: Jiangsu Province Hospital, Nanjing Medical University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Bristol-Myers Squibb

OpenAlex ID: W4402558417

FWCI:

Cites:

Cited by:

Related to: 10